News

FDA approves first generic form of oxiconazole nitrate cream


 

References

A generic formulation of oxiconazole nitrate cream, 1% has been approved by the Food and Drug Administration, for the treatment of tinea pedis, tinea cruris, tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum) and tinea (pityriasis) versicolor due to Malassezia furfur.

This is the first generic version of Oxistat to be approved, according to the FDA’s statement announcing the approval.

The label for the generic, manufactured by Taro Pharmaceuticals U.S.A. is available here.

emechcatie@frontlinemedcom.com

Recommended Reading

Judicious Use of Antibiotics in Dermatology
MDedge Dermatology
EHR Report: How Zika virus reveals the fault in our EHRs
MDedge Dermatology
Clinical Pearl: The Squeeze Maneuver
MDedge Dermatology
Maximizing bang in topical onychomycosis therapy
MDedge Dermatology
Necrotizing Cellulitis With Multiple Abscesses on the Leg Caused by Serratia marcescens
MDedge Dermatology
When toenail onychomycosis can turn deadly
MDedge Dermatology
Study: Two varicella vaccination doses more effective than one
MDedge Dermatology
Flu vaccination found safe in surgical patients
MDedge Dermatology
Antivirals, pain relief, rest are key to zoster management
MDedge Dermatology
As varicella recedes, zoster rises: The question is ‘why?’
MDedge Dermatology